Medical device maker Medtronic plc MDT recently announced the receipt of FDA approval for its Claria MRI Quad Cardiac Resynchronization Therapy Defibrillator (CRT-D) SureScan device for the treatment ...

Minnesota-based leading medical device manufacturer Medtronic, Inc.'s (MDT) Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy ...

Please provide your email address to receive an email when new articles are posted on . Among the features of the new European Society of Cardiology guideline on pacing and cardiac resynchronization ...

PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.

MINNEAPOLIS, USA and NICE, FRANCE - June 18, 2014 - New data from the Medtronic, Inc. (MDT) Adaptive CRT trial show a 61 percent (p=0.01) lower risk of atrial fibrillation (AF)-related problems in ...

Report Ocean has published a new report on the Cardiac Resynchronization Therapy (CRT) Devices Market, delivering an extensive analysis of key factors such as market restraints, drivers, and ...

Medtronic announced Friday that FDA has approved the the first MR-conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure in the U.S. The Medtronic ...

Itrevia HF-T QP boasts of latest defibrillator technology, closed loop stimulation and compatibility with a quadripolar lead, to help patients with heart failure conditions BIOTRONIK, a manufacturer ...

The EchoCRT Study Will Investigate the Life-Saving Benefits of Cardiac Resynchronization Therapy in Patients with Heart Failure Who Currently Do Not Receive Device Therapy BERLIN, Germany & LAKE ...

MINNEAPOLIS - Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization ...

On the heels of a unanimous FDA panel recommendation in March for an expanded indication of Boston Scientific's (Natick, Massachusetts) cardiac resynchronization therapy defibrillators (CRT-Ds), ...